Premature babies have an increased risk of developing bronchopulmonary dysplasia (BPD), a serious lung disease, which is a major cause of death and lifelong complications. Researchers have conducted a Phase I clinical trial to assess the safety and efficacy of stem cell therapies in premature babies to prevent or treat BPD. The results showed an reduction in the severity of the disease.
Dr Park said “These findings strongly suggest that phase II clinical trials are warranted to test the efficacy of mesencyhmal stem cell transplantation, which could lead to new therapies to prevent or cure BPD.”
For the full article click here.
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.